Opgen Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Opgen has an operating margin of 6.3%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 31/100, indicating healthy but not exceptional operating efficiency. This is up from -899.5% the prior year.
Opgen's revenue surged 52.0% year-over-year to $5.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Opgen carries a low D/E ratio of 0.34, meaning only $0.34 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.18, Opgen holds $4.18 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Opgen earns a strong 162.5% return on equity (ROE), meaning it generates $162 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Opgen scores -39.73, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.3M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Opgen passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Opgen generates $-0.41 in operating cash flow (-$4.9M OCF vs $12.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Opgen earns $43.0 in operating income for every $1 of interest expense ($325K vs $8K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Opgen (OPGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Opgen generated $5.2M in revenue in fiscal year 2024. This represents an increase of 52.0% from the prior year.
Opgen's EBITDA was $499K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 101.7% from the prior year.
Opgen reported $12.0M in net income in fiscal year 2024. This represents an increase of 136.7% from the prior year.
Opgen earned $2.30 per diluted share (EPS) in fiscal year 2024. This represents an increase of 105.5% from the prior year.
Opgen held $1.3M in cash against $0 in long-term debt as of fiscal year 2024.
Opgen had 10M shares outstanding in fiscal year 2024. This represents an increase of 685.1% from the prior year.
Opgen's operating margin was 6.3% in fiscal year 2024, reflecting core business profitability. This is up 905.8 percentage points from the prior year.
Opgen's net profit margin was 230.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 1186.5 percentage points from the prior year.
Opgen's ROE was 162.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Opgen invested $49K in research and development in fiscal year 2024. This represents a decrease of 99.0% from the prior year.
OPGN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $4.0M | N/A | N/A | $28K-83.3% | $168K-84.3% | $1.1M+53.0% | $699K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $73K-93.7% | $1.2M+87.2% | $619K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $95K+206.9% | -$89K-210.7% | $80K |
| R&D Expenses | N/A | N/A | N/A | $488-97.9% | $23K-11.2% | $26K-92.1% | $329K-72.6% | $1.2M |
| SG&A Expenses | $702K+18.0% | $595K+15.9% | $513K-33.2% | $769K-51.0% | $1.6M-6.9% | $1.7M+40.6% | $1.2M-41.1% | $2.0M |
| Operating Income | -$702K-120.6% | $3.4M+750.8% | -$523K+33.3% | -$784K+49.3% | -$1.5M+11.3% | -$1.7M+89.7% | -$17.0M-375.6% | -$3.6M |
| Interest Expense | $4K+141.3% | $2K-49.9% | $3K0.0% | $3K+200.1% | $1K | $0-100.0% | $140K-64.6% | $397K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$609K-117.3% | $3.5M+960.0% | -$408K-104.6% | $8.9M+666.6% | -$1.6M-647.4% | $288K+101.7% | -$17.0M-319.4% | -$4.1M |
| EPS (Diluted) | $-0.06-117.6% | $0.34+950.0% | $-0.04-103.0% | $1.35 | $-1.18-886.7% | $0.15+100.6% | $-23.38 | $-4.63 |
OPGN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.6M-4.6% | $13.2M+40.6% | $9.4M-4.5% | $9.9M+243.7% | $2.9M-0.1% | $2.9M+52.6% | $1.9M-89.6% | $18.1M |
| Current Assets | $5.5M-9.7% | $6.1M+173.3% | $2.2M-15.5% | $2.6M+362.5% | $573K+7.5% | $533K-66.3% | $1.6M-54.3% | $3.5M |
| Cash & Equivalents | $414K-50.2% | $832K-25.3% | $1.1M-15.1% | $1.3M+679.6% | $168K-37.2% | $267K-76.8% | $1.2M+293.6% | $293K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.8M |
| Accounts Receivable | $4.0M+0.1% | $4.0M+11745.8% | $34K+16.5% | $29K+15.2% | $25K-33.1% | $38K-63.3% | $103K-75.6% | $423K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.5M-3.8% | $2.6M+9.0% | $2.4M-4.7% | $2.5M-82.9% | $14.5M+6.3% | $13.7M+1.8% | $13.4M-13.0% | $15.5M |
| Current Liabilities | $782K-5.4% | $827K+46.8% | $563K-11.1% | $634K-95.0% | $12.6M+7.7% | $11.7M+2.4% | $11.4M-8.4% | $12.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.2M |
| Total Equity | $10.2M-4.8% | $10.7M+51.2% | $7.1M-4.4% | $7.4M+163.3% | -$11.7M-7.9% | -$10.8M+6.5% | -$11.6M-531.9% | $2.7M |
| Retained Earnings | -$291.0M-0.2% | -$290.4M+1.2% | -$293.9M-0.1% | -$293.5M+4.3% | -$306.8M-0.5% | -$305.2M+0.1% | -$305.5M-5.9% | -$288.5M |
OPGN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$333K+25.5% | -$447K-126.1% | -$198K+14.8% | -$232K+67.8% | -$720K+33.6% | -$1.1M+35.3% | -$1.7M+42.7% | -$2.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $914-99.1% | $102K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$1.7M+44.6% | -$3.0M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$914+99.1% | -$102K |
| Financing Cash Flow | -$84K | N/A | N/A | -$90K-114.5% | $621K+210.9% | $200K-90.5% | $2.1M+7518.3% | $28K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OPGN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 56.5%+64.8pp | -8.3%-19.8pp | 11.5% |
| Operating Margin | N/A | 85.1% | N/A | N/A | -5526.1%-4488.2pp | -1038.0%+547.2pp | -1585.1%-1075.0pp | -510.1% |
| Net Margin | N/A | 87.8% | N/A | N/A | -5629.8%-5801.1pp | 171.3%+1764.4pp | -1593.1%-1011.9pp | -581.2% |
| Return on Equity | N/A | 32.9% | N/A | 299.1% | N/A | N/A | N/A | N/A |
| Return on Assets | -4.8%-31.3pp | 26.5%+30.8pp | -4.3%-167.6pp | 163.3%+218.2pp | -54.9%-65.0pp | 10.0%+915.4pp | -905.4%-883.0pp | -22.4% |
| Current Ratio | 7.06-0.3 | 7.39+3.4 | 3.97-0.2 | 4.18+4.1 | 0.050.0 | 0.05-0.1 | 0.14-0.1 | 0.28 |
| Debt-to-Equity | 0.240.0 | 0.24-0.1 | 0.340.0 | 0.34+1.6 | -1.25+0.0 | -1.27-0.1 | -1.16-4.6 | 3.44 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -156.8%+276.6pp | -433.4% |
Similar Companies
Frequently Asked Questions
What is Opgen's annual revenue?
Opgen (OPGN) reported $5.2M in total revenue for fiscal year 2024. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Opgen's revenue growing?
Opgen (OPGN) revenue grew by 52% year-over-year, from $3.4M to $5.2M in fiscal year 2024.
Is Opgen profitable?
Yes, Opgen (OPGN) reported a net income of $12.0M in fiscal year 2024, with a net profit margin of 230.8%.
What is Opgen's earnings per share (EPS)?
Opgen (OPGN) reported diluted earnings per share of $2.30 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Opgen's EBITDA?
Opgen (OPGN) had EBITDA of $499K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Opgen's operating margin?
Opgen (OPGN) had an operating margin of 6.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Opgen's net profit margin?
Opgen (OPGN) had a net profit margin of 230.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Opgen's return on equity (ROE)?
Opgen (OPGN) has a return on equity of 162.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Opgen's operating cash flow?
Opgen (OPGN) generated -$4.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Opgen's total assets?
Opgen (OPGN) had $9.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Opgen spend on research and development?
Opgen (OPGN) invested $49K in research and development during fiscal year 2024.
How many shares does Opgen have outstanding?
Opgen (OPGN) had 10M shares outstanding as of fiscal year 2024.
What is Opgen's current ratio?
Opgen (OPGN) had a current ratio of 4.18 as of fiscal year 2024, which is generally considered healthy.
What is Opgen's debt-to-equity ratio?
Opgen (OPGN) had a debt-to-equity ratio of 0.34 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Opgen's return on assets (ROA)?
Opgen (OPGN) had a return on assets of 121.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Opgen's cash runway?
Based on fiscal year 2024 data, Opgen (OPGN) had $1.3M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Opgen's Altman Z-Score?
Opgen (OPGN) has an Altman Z-Score of -39.73, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Opgen's Piotroski F-Score?
Opgen (OPGN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Opgen's earnings high quality?
Opgen (OPGN) has an earnings quality ratio of -0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Opgen cover its interest payments?
Opgen (OPGN) has an interest coverage ratio of 43.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Opgen?
Opgen (OPGN) scores 86 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.